Several other BiTEs are currently in clinical trials for various human cancer types, all targeting tumor-specific antigens, including epithelial cell adhesion molecule (EpCAM), carcinoembryonic antigen, CD123, and CD20 15. The gene discussed is EPCAM; the disease is cancer.